Veralox Therapeutics has raised $48M in total funding. Backed by JDRF T1D Fund, Sanofi Ventures, VTC Innovation and VTC Seed Fund.
Veralox Therapeutics funding overview
Veralox Therapeutics has raised $48M in total disclosed funding. That places its disclosed total in the $25M–$100M range. The round record for Veralox Therapeutics runs through 2023; nothing later has been disclosed. Investors on record include JDRF T1D Fund, Sanofi Ventures, VTC Innovation and VTC Seed Fund, Maryland Momentum Fund, University of Vermont Health Network, TEDCO. 6 distinct backers are named across the disclosed rounds.
Veralox Therapeutics at a glance
Total raised
$48M
Latest round date
June 2023
Notable investors
JDRF T1D Fund, Sanofi Ventures, VTC Innovation and VTC Seed Fund, Maryland Momentum Fund, University of Vermont Health Network, TEDCO
Frequently asked about Veralox Therapeutics funding
How much has Veralox Therapeutics raised?
Veralox Therapeutics has raised $48M in total disclosed funding across the rounds on record.
Who has invested in Veralox Therapeutics?
JDRF T1D Fund, Sanofi Ventures, VTC Innovation and VTC Seed Fund, Maryland Momentum Fund, University of Vermont Health Network, TEDCO are named among the investors backing Veralox Therapeutics.
What was the latest Veralox Therapeutics funding round?
No round stage has been disclosed for Veralox Therapeutics.
Where is Veralox Therapeutics based?
No headquarters location is disclosed for Veralox Therapeutics.
When did Veralox Therapeutics last raise?
The last disclosed Veralox Therapeutics round closed in June 2023.
Veralox Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies below to benchmark round size and investor mix.
